Three-armed study for therapy of primary and secondary syphilis in HIV infection

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00000389

Enrollment

150

Registered

2010-05-25

Start date

2004-08-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A53.9

Interventions

Group 1: ceftriaxone 1g i.v. for 10 days Group 2: Bezathine penicillin 2x1,2 Mio i.E. i.m. once Group 3: benzathine penicillin 2x 1,2 Mio i.E. i.m. day 1, 8, 15

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: -HIV positive Patients with serologically proven early syphilis

Exclusion criteria

Exclusion criteria: -known sensibilization agaist ß-lactam antibiotics -patients that were treated within the last 48h with an agent that is active against treponema pallidum -pregnant or lactating women -patients with late syphilis (latent syphilis of unknown duration, tertiary syphilis or neuro syphilis

Design outcomes

Primary

Measure	Time frame
treatment failure defined as: -retreatment or -treatment with any antibiotic active against treponema pallidum or -no reduction by 2 titer levels in VDRL or FTAabs19S IgM after 48 weeks	—

Countries

Germany

Contacts

Public ContactAnja Potthoff

St. Josef Hospital Interdisziplinäre Immunologische Ambulanz

a.potthoff@klinikum-bochum.de0234/5092334

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026